Literature DB >> 15351350

Strategies for hepatitis C therapeutic intervention: now and next.

Seng-Lai Tan1, Yupeng He, Ying Huang, Michael Gale.   

Abstract

Interferon-alpha-based therapies are the mainstay of hepatitis C treatment. However, these broad immunomodulatory agents, already limited by their side effects, expense and route of administration, are not efficacious in all cases. Therefore, research efforts have focused on identifying additional drugs and therapeutic modalities to benefit those individuals refractive to current therapy, and which might be more affordable, such as orally active small-molecule alternatives and preventive or therapeutic vaccines. It is likely that successful therapeutic intervention of hepatitis C will require a combination of approaches targeting different aspects of the viral life-cycle.

Mesh：

Substances：

Year:  2004        PMID： 15351350     DOI： 10.1016/j.coph.2004.07.003

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  8 in total

1.  Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C.

Authors:  Ying Huang; Jordan J Feld; Ronda K Sapp; Santosh Nanda; Jiing-Huey Lin; Lawrence M Blatt; Michael W Fried; Krishna Murthy; T Jake Liang
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

2.  Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.

Authors:  Ayaz M Majid; Heather Ezelle; Sangeeta Shah; Glen N Barber
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection.

Authors:  Ying Huang; Huiying Yang; Brian B Borg; Xiaowen Su; Shannon L Rhodes; Kai Yang; Xiaomei Tong; George Tang; Charles D Howell; Hugo R Rosen; Chloe L Thio; David L Thomas; Harvey J Alter; Ronda K Sapp; T Jake Liang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-10       Impact factor: 11.205

4.  Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.

Authors:  Yueh-Ming Loo; David M Owen; Kui Li; Andrea K Erickson; Cynthia L Johnson; Penny M Fish; D Spencer Carney; Ting Wang; Hisashi Ishida; Mitsutoshi Yoneyama; Takashi Fujita; Takeshi Saito; William M Lee; Curt H Hagedorn; Daryl T-Y Lau; Steven A Weinman; Stanley M Lemon; Michael Gale
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

5.  Negative regulation of interferon-β gene expression during acute and persistent virus infections.

Authors:  Junqiang Ye; Tom Maniatis
Journal:  PLoS One       Date:  2011-06-03       Impact factor: 3.240

6.  Transcriptome and comparative gene expression analysis of Sogatella furcifera (Horváth) in response to southern rice black-streaked dwarf virus.

Authors:  Yi Xu; Wenwu Zhou; Yijun Zhou; Jianxiang Wu; Xueping Zhou
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

Review 7.  Systems biology and the host response to viral infection.

Authors:  Seng-Lai Tan; Gopinath Ganji; Bryan Paeper; Sean Proll; Michael G Katze
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

8.  Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependant RNA polymerase: 2-aryl-3-heteroaryl-1,3-thiazolidin-4-one derivatives.

Authors:  Ravindra K Rawal; S B Katti; Neerja Kaushik-Basu; Payal Arora; Zhenhua Pan
Journal:  Bioorg Med Chem Lett       Date:  2008-10-08       Impact factor: 2.823
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.